Alzheimer's Disease Mitochondria-Targeting Companies

Overview

Overview

This category covers biotechnology and pharmaceutical companies developing therapeutics that target mitochondrial dysfunction, autophagy, and lysosomal pathways in Alzheimer's disease. These approaches address the fundamental cellular energy deficits and protein clearance mechanisms that are central to AD pathogenesis.

Mitochondrial dysfunction is one of the earliest and most prominent features of Alzheimer's disease, preceding clinical symptoms by decades. Impairments in mitochondrial complex IV (cytochrome c oxidase), reduced ATP production, and increased oxidative stress contribute to synaptic failure and neuronal death. Autophagy-lysosomal pathway dysfunction leads to accumulation of damaged proteins and organelles, exacerbating [amyloid-beta](/proteins/amyloid-beta) and [tau](/proteins/tau) pathology.

Key Companies

Mitochondrial Function Companies

Vandria SA

• Focus: Mitochondrial quality control and cellular energetics
• Lead Candidate: VNA-318
• Indication: Alzheimer's disease
• Stage: Phase 1
• Mechanism: Mitochondrial modulator targeting neuronal survival
• Notes: Swiss-based company with dual programs in AD and PD
• Page: [Vandria SA](/companies/vandria)

Clene Nanomedicine

• Focus: Nanotherapeutic approach to cellular energy impairment
• Lead Candidate: CNM-Au8
• Indication: Alzheimer's disease (exploratory)
• Stage: Clinical
• Mechanism: Gold nanocrystals catalyze redox reactions to support mitochondrial function and reduce oxidative stress
• Notes: Primarily focused on ALS and PD, with AD as emerging indication
• Page: [Clene Nanomedicine](/companies/clene)

Cyteir Therapeutics

• Focus: Mitochondrial dynamics and quality control
• Mechanism: Targeting mitochondrial DNA repair and dynamics
• Stage: Discovery/Preclinical
• Notes: Company focuses on mitochondrial function in neurodegeneration

Autophagy-Enhancing Companies

Retro Biosciences

• Focus: Autophagy and cellular clearance
• Lead Candidate: RB-001
• Indication: Alzheimer's disease
• Stage: Phase 1
• Mechanism: Autophagy enhancement to clear protein aggregates
• Notes: Also developing senolytic approaches
• Page: [Retro Biosciences](/companies/retro-biosciences)

Alector Inc.

• Focus: Lysosomal function and TREM2 biology
• Lead Candidates: AL002, AL044
• Indication: Alzheimer's disease
• Stage: Phase 1/2
• Mechanism: TREM2 agonist to enhance microglial lysosomal function and phagocytosis
• Notes: Pioneering immune-neurology approach
• Page: [Alector](/companies/alector)

Companies with Multiple Mechanisms

AC Immune SA

• Focus: Tau pathology and neuroinflammation
• Lead Candidates: ACI-35.030 (tau vaccine), ACI-35.050
• Indication: Alzheimer's disease
• Stage: Phase 2
• Mechanism: Liposomal vaccine targeting phosphorylated tau; also addressing lysosomal dysfunction
• Notes: Swiss-based company with multiple CNS programs
• Page: [AC Immune](/companies/ac-immune)

Prothelia

• Focus: Protein homeostasis and synaptic protection
• Lead Candidates: PROT-003
• Indication: Alzheimer's disease
• Stage: Preclinical
• Mechanism: Targeting protein aggregation and cellular clearance pathways
• Page: [Prothelia](/companies/prothelia)

Gain Therapeutics

• Focus: Protein stabilization
• Lead Candidates: GT-02287
• Indication: Alzheimer's disease
• Stage: Preclinical
• Mechanism: Allosteric modulators to stabilize misfolded proteins and enhance lysosomal clearance
• Page: [Gain Therapeutics](/companies/gain-therapeutics)

Additional Mitochondria-Focused Companies

| Company | Focus | Mechanism | Stage |
|---------|-------|-----------|-------|
| Neuromito Therapeutics | Mitochondrial function | Small molecule mitochondrial modulators | Discovery |
| MitoRestore Pharmaceuticals | Mitochondrial dynamics | Mitochondrial quality control enhancers | Preclinical |
| Cytochrome Therapeutics | Cytochrome c function | Cytochrome c oxidase support | Discovery |

Therapeutic Mechanisms

Mitochondrial Targeting Approaches

Autophagy-Lysosomal Pathways

Pipeline Summary

| Company | Drug | Mechanism | Phase | Target |
|---------|------|-----------|-------|--------|
| Vandria | VNA-318 | Mitochondrial modulator | Phase 1 | Mitochondria |
| Clene | CNM-Au8 | Nanocatalyst | Clinical | Mitochondria/Oxidative stress |
| Retro Biosciences | RB-001 | Autophagy enhancer | Phase 1 | Autophagy |
| Alector | AL002 | TREM2 agonist | Phase 1/2 | Lysosomal function |
| AC Immune | ACI-35.030 | Tau vaccine | Phase 2 | Tau/Neuroinflammation |
| Gain Therapeutics | GT-02287 | Protein stabilizer | Preclinical | Lysosomal function |

Research Context

Mitochondrial dysfunction in Alzheimer's disease is characterized by:

• Early Complex IV Deficiency: Loss of cytochrome c oxidase activity precedes other pathological changes
• Oxidative Stress: Increased reactive oxygen species damaging proteins, lipids, and DNA
• Calcium Dysregulation: Impaired mitochondrial calcium handling affects synaptic function
• Metabolic Shift: Shift from oxidative phosphorylation to glycolysis, reducing ATP output
• Mitophagy Defects: Impaired clearance of damaged mitochondria leads to accumulation of dysfunctional organelles

• Lysosomal Acidification Defects: Reduced lysosomal enzyme activity in neurons
• Autophagosome Accumulation: Impaired fusion between autophagosomes and lysosomes
• TREM2 Dysfunction: Reduced microglial phagocytic capacity
• Protein Aggregate Sequestration: Failure to clear amyloid and tau aggregates

Cross-Links

• [Mitochondrial Dysfunction in Alzheimer's Disease](/mechanisms/mitochondrial-dysfunction)
• [Autophagy in Neurodegeneration](/mechanisms/autophagy)
• [Lysosomal Dysfunction](/mechanisms/lysosomal-dysfunction)
• [Neuroinflammation Pathways](/mechanisms/neuroinflammation-pathway)
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
• [AD Pipeline Companies](/companies/ad-pipeline-companies)
• [AD Senolytic Therapy Companies](/companies/ad-senolytic-therapy-companies)
• [Emerging Novel Mechanism AD Companies](/companies/emerging-novel-mechanism-ad-companies-2024-2025)

References